| abstract |
A coformulation of an active (preferably pharmaceutically active, for instance a COX-2 enzyme inhibitor) substance and an oligomeric or polymeric excipient, containing at least 10% of the active, between 80 and 100% of which is amorphous. The amorphous phase is stable, with respect to the crystalline phase(s), for at least three months after its preparation when stored at between 0 and 10{C. The invention also provides processes, preferably involving SEDS<SP>TM</SP> particle formation, for preparing such a coformulation. |